Top-Rated Charity
Website
View similar charities
Ratings & Metrics
Financial Documents
| Entity | Document Type | Tax ID |
|---|---|---|
| Cancer Research Institute | IRS Form 990 | 13-1837442 |
| Cancer Research Institute | Audited Financial Statements | 13-1837442 |
|
Entity: Cancer Research Institute Document Type: IRS Form 990 Tax ID: 13-1837442 |
|
Entity: Cancer Research Institute Document Type: Audited Financial Statements Tax ID: 13-1837442 |
Governance & Transparency
CharityWatch evaluates certain criteria related to a charity's Governance and Transparency. Donors may want to consider a charity's willingness to be open and transparent with CharityWatch to be a good litmus test for determining its commitment to public accountability.
Top Salaries
| Name | Title | Compensation | |
|---|---|---|---|
| 1 | Jill O'Donnell-Tormey | CEO/Director of Scientific Affairs | $464,756 |
| 2 | Alfred R. Massidas | CFO/Director of HR | $348,306 |
| 3 | Lynne Rapino | Director, Grants Administration & Special Events | $294,569 |
|
1 Name: Jill O'Donnell-Tormey Title: CEO/Director of Scientific Affairs Compensation: $464,756 |
|
2 Name: Alfred R. Massidas Title: CFO/Director of HR Compensation: $348,306 |
|
3 Name: Lynne Rapino Title: Director, Grants Administration & Special Events Compensation: $294,569 |
Analysts' Notes
CharityWatch Analysts perform an in-depth analysis of charities' audited financial statements and IRS tax filings, and often review other documents such as state filings, annual reports, and fundraising contracts during their evaluations. Below are select notes that CharityWatch believes may be of interest to donors.
| According to the Cancer Research Institute audit of June 30, 2018 (Note A-14, Contributed services), the Institute received contributed services provided by the Institute's Scientific Advisory Council in fiscal 2018 on which it placed a total value of $501,615. [Note: CharityWatch generally excludes the value of in-kind (non-cash) donations of goods and services from its calculations of Program % and Cost to Raise $100. More information on how grades are calculated and the treatment of in-kind donations can be found on the Our Process page.] |
| According to the Cancer Research Institute audit of June 30, 2018 (Note B, Contributions and Grants and Other Receivables): "... Included in contribution revenue for fiscal-year 2018, was an amount of $6,914,717 from two donors, which represented approximately 56% of the total operating support and revenue for that fiscal year.." |
| According to the Cancer Research Institute audit of June 30, 2018 (Note A-13, Contributions): "The Institute has entered into various clinical research support agreements to conduct clinical trials of cancer immunotherapies. The clinical trials are co-funded by various parties who have provided support in the amount of approximately $6,914,717 through June 30, 2018." |
| According to the Cancer Research Institute audit of June 30, 2018 (Note L, Financial Investment): "In 2010, the Institute entered into a joint venture with the Ludwig Institute for Cancer Research Ltd. and formed a U.S. company named Cancer Vaccine Acceleration Company, LLC ('CVAC'). The members' initial capital contribution was $200. The purpose of the company is to obtain, hold, and develop intellectual property and other assets related to research and development of a vaccine for cancer in furtherance of the respective charitable missions of the members. The Institute believes that at present, the value of this investment is not material." |